down arrow

InflaRx NV

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0012661870
USD
1.10
0.11 (10.65%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.991.11

52 Week

0.712.81
Valuation
Technical
Day's Volume

CASH

134.57 k

Shareholding (Mar 2025)

FII

1.18%

Held by 11 FIIs

DII

98.37%

Held by 3 DIIs

Promoter

0.00%

How big is InflaRx NV?

22-Jun-2025

As of Jun 18, InflaRx NV has a market capitalization of 51.69 million, with net sales of 0.19 million and a net profit of -53.31 million over the latest four quarters. The company reported shareholder's funds of 63.60 million and total assets of 78.72 million as of Dec 24.

Market Cap: As of Jun 18, InflaRx NV has a market capitalization of 51.69 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, InflaRx NV reported net sales of 0.19 million and a net profit of -53.31 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 63.60 million and total assets of 78.72 million.

Read More

What does InflaRx NV do?

22-Jun-2025

InflaRx NV is a clinical-stage biopharmaceutical company developing monoclonal antibodies for life-threatening inflammatory diseases, with a market cap of $51.69 million and a recent net profit of -$9 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap firm.

Overview: <BR>InflaRx NV is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for the treatment of life-threatening inflammatory diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 51.69 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.93 <BR>Return on Equity: -70.03% <BR>Price to Book: 0.68<BR><BR>Contact Details: <BR>Address: Winzerlaer Str. 2, JENA None: 07745 <BR>Tel: 49 3641 508180 <BR>Website: https://www.inflarx.de/

Read More

Is InflaRx NV technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, InflaRx NV's trend is mildly bearish, influenced by bearish daily moving averages and weekly Dow Theory, despite a mildly bullish MACD; it has significantly underperformed the S&P 500 with a year-to-date return of -44.53%.

As of 8 September 2025, the technical trend for InflaRx NV has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, and weekly Dow Theory also showing a mildly bearish outlook. While the MACD is mildly bullish on both weekly and monthly timeframes, the overall sentiment is tempered by the bearish signals from Bollinger Bands and KST on the monthly timeframe. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -44.53% compared to the S&P 500's 12.22%, highlighting its weak performance over multiple periods.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 106 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.83

stock-summary
Return on Equity

-99.42%

stock-summary
Price to Book

1.58

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-16 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.42%
0%
-36.42%
6 Months
25.0%
0%
25.0%
1 Year
-51.11%
0%
-51.11%
2 Years
-18.52%
0%
-18.52%
3 Years
-57.53%
0%
-57.53%
4 Years
-73.24%
0%
-73.24%
5 Years
-72.43%
0%
-72.43%

InflaRx NV for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is InflaRx NV technically bullish or bearish?

As of 8 September 2025, the technical trend for InflaRx NV has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, and weekly Dow Theory also showing a mildly bearish outlook. While the MACD is mildly bullish on both weekly and monthly timeframes, the overall sentiment is tempered by the bearish signals from Bollinger Bands and KST on the monthly timeframe. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -44.53% compared to the S&P 500's 12.22%, highlighting its weak performance over multiple periods....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.54%
EBIT Growth (5y)
-0.43%
EBIT to Interest (avg)
-57.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.87%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.73
EV to EBIT
0.24
EV to EBITDA
0.25
EV to Capital Employed
-2.77
EV to Sales
-14.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-70.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (0.45%)

Foreign Institutions

Held by 11 Foreign Institutions (1.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -86.36% vs 54.17% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.60",
          "val2": "-14.10",
          "chgp": "-10.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.00",
          "val2": "6.40",
          "chgp": "-84.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.40",
          "val2": "-8.80",
          "chgp": "-86.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-351,387.80%",
          "val2": "0.00%",
          "chgp": "-35,138.78%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 100.00% vs 0.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.03% vs -48.71% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-62.50",
          "val2": "-62.20",
          "chgp": "-0.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.50",
          "val2": "14.20",
          "chgp": "-61.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.80",
          "val2": "-46.10",
          "chgp": "-8.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-351,628.80%",
          "val2": "-921,291.50%",
          "chgp": "56,966.27%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.60
-14.10
-10.64%
Interest
0.00
0.00
Exceptional Items
1.00
6.40
-84.38%
Consolidate Net Profit
-16.40
-8.80
-86.36%
Operating Profit Margin (Excl OI)
-351,387.80%
0.00%
-35,138.78%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -86.36% vs 54.17% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.20
0.10
100.00%
Operating Profit (PBDIT) excl Other Income
-62.50
-62.20
-0.48%
Interest
0.00
0.00
Exceptional Items
5.50
14.20
-61.27%
Consolidate Net Profit
-49.80
-46.10
-8.03%
Operating Profit Margin (Excl OI)
-351,628.80%
-921,291.50%
56,966.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.03% vs -48.71% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About InflaRx NV stock-summary
stock-summary
InflaRx NV
Pharmaceuticals & Biotechnology
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Company Coordinates stock-summary
Company Details
Winzerlaer Str. 2 , JENA None : 07745
stock-summary
Tel: 49 3641 508180
stock-summary
https://www.inflarx.de/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."